Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03759184
Title Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Obinutuzumab + rhIL-15

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.